<SEC-DOCUMENT>0001144204-14-043110.txt : 20140715
<SEC-HEADER>0001144204-14-043110.hdr.sgml : 20140715
<ACCEPTANCE-DATETIME>20140715160734
ACCESSION NUMBER:		0001144204-14-043110
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20140715
DATE AS OF CHANGE:		20140715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-190897
		FILM NUMBER:		14975992

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>v383919_424b3.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT NO. 6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-190897</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus Supplement No. 6 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(to Prospectus dated April 9, 2014) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,227,631 Shares </B></P>

<P STYLE="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC. </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement supplements
the prospectus, dated April 9, 2014 (the &ldquo;Prospectus&rdquo;), which forms a part of our Post-Effective Amendment No. 1 to
our Registration Statement on Form S-1 (Registration No. 333-190897). This prospectus supplement is being filed to update, amend
and supplement the information included or incorporated by reference in the Prospectus with the information contained in our current
report on Form 8-K, filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) on July 15, 2014 (the &ldquo;Current
Report&rdquo;). Accordingly, we have attached the Current Report to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Prospectus and this prospectus supplement
relate to the sale or other disposition from time to time of up to 5,227,631 shares of our common stock, which are held by the
selling stockholders named in the Prospectus<I>.</I> The shares of common stock covered by the Prospectus and this prospectus supplement
were previously issued by us in a private placement. We are not selling any common stock under the Prospectus and this prospectus
supplement and will not receive any of the proceeds from the sale or other disposition of shares by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement should be read
in conjunction with the Prospectus. This prospectus supplement updates, amends and supplements the information included or incorporated
by reference in the Prospectus and the prospectus supplements dated April 29, 2014, May 13, 2014, May 15, 2014, May 27, 2014 and
June 11, 2014. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should
rely on the information in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is quoted on The NASDAQ
Capital Market under the symbol &ldquo;LPCN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Investing in our common stock involves a high degree of
risk. You should review carefully the risks and uncertainties described under the heading &ldquo;<U>Risk Factors</U>&rdquo; beginning
on page 5 of the Prospectus, and under similar headings in any amendment or supplements to the Prospectus. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
July 15, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>July 15, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 75%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center"><FONT STYLE="font-size: 10pt">99-0370688</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer<BR>
Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)(Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item&nbsp;8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Events</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 15, 2014, Lipocine Inc. issued a press release to report
the issuance of a U.S. Patent for LPCN 1021. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD>Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><U>Exhibit No.</U></FONT></TD><TD><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt">99.1</FONT></TD><TD><FONT STYLE="font-size: 10pt">Press Release Announcing Issuance
of U.S. Patent for LPCN 1021</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">LIPOCINE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 16%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">July 15, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>For Immediate Release</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Lipocine Announces Issuance of U.S. Patent for
LPCN 1021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>SALT
LAKE CITY (July 15, 2014) &ndash;</B> Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today</FONT>
<FONT STYLE="font-size: 10pt">announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent number
8,778,922, entitled &ldquo;Steroidal Compositions.&rdquo; This patent relates to pharmaceutical compositions having testosterone
undecanoate. The patent is expected to provide protection through January 2029 for LPCN 1021. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;This addition to our intellectual
property portfolio, which we believe will be listed in the Food and Drug Administration Orange Book, has the potential to significantly
lengthen our exclusivity period for LPCN 1021,&rdquo; said Dr. Mahesh Patel, President and CEO of Lipocine Inc. &ldquo;We look forward
to presenting top-line data from our pivotal phase 3 study, or SOAR trial, for LPCN 1021 in the third quarter of this year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">LPCN 1021 is a twice-a-day, oral product
with low gastro-intestinal drug exposure that we expect will overcome the major shortcomings of existing products with a more patient/
physician friendly label that includes three simple dosing options and faster time to maintenance dose in most patients, which
we expect will improve patient compliance. Unlike a selective estrogen receptor modulator (&ldquo;SERM&rdquo;), LPCN 1021 is not
designed to interact with estrogen receptors and is targeted to address an unmet oral option needed in the established testosterone
replacement market for chronic use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men&rsquo;s and women&rsquo;s health using its proprietary drug delivery technologies. Lipocine&rsquo;s
lead product candidate, LPCN 1021, currently in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of
testosterone replacement therapy. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy
product, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the
prevention of recurrent preterm birth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This release contains &ldquo;forward
looking statements&rdquo; that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995 and includes statements that are not historical facts relating to the potential uses and benefits of Lipocine&rsquo;s product candidates
and product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties,
including, without limitation, the risks related to the receipt of regulatory approvals, the results of clinical trials, patient
acceptance of Lipocine&rsquo;s products, the manufacturing and commercialization of Lipocine&rsquo;s products, and other risks detailed in
Lipocine&rsquo;s filings with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), including, without limitation, its Form
10-K and other reports on Form 8-K, all of which can be obtained on the Company&rsquo;s website at www.lipocine.com or on the SEC website
at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTACT: &#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President &amp; Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: mb@lipocine.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (443) 213-0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">john.woolford@westwicke.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``T`.$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]]6((.#@D
M>N*^1_VG?^"SGP/_`&3_`(RS>!?$>KZQ?ZW8;!JQTFS-W#H[,H;9,P/WPI#,
MBY*@C//%?2'COXL^&/A7;6MQXG\0Z%X?ANY`D$FI7T5JLS9Z+O(S^%?A9^WM
M_P`$L?CAI?[8OCG4_#/@C6_'OASQQKMUXATC6])V36SQ7<IFVSR%@(BA;!9N
M"H!!Q65>4HJ\%<_2_#+A?)<XQTZ6?XAT*2@W%W45)K=*4M--[;L^]?\`@LK_
M`,%,]=_9T_9Q^'NH?"#6+"2?XJ2/-I_B6*-;J&&R2)9=\08;2[[QC/W1GC->
M8_\`!#3_`(*?_$[]HOXY:]\-?B9K1\7*VC2:YIFK36\<%S9F&1$DBD*`*R,)
M%()&05(SS7G/Q,^'?B[PK^R5\/O@;<?"+0?VE?A]X!T6*76[SX<>,[<^-?".
MOR3SS3K;V^XB2&-)4C`"G>`V[L!S/[.?[1'P@_8_\->&_%_PNTW4X_@_\5+F
M_P#AG\4/%WBH2?\`"9_#/79!LL8+N)=L5K9AV)8A"78JQ<;$4KEGSJ5].Q[,
M,[X0P_#6)R-T.?%>T:A6Y5K'F]V?->ZM'[*6I^@4/_!;C]GJ;X_#X?\`_"73
MBZ:\&FKK3VK#1S=;]GE_:#P%W_+YF-F<?-CFOK:)SO7G'//.:_G`L_\`@D7^
MT%>?%6/X?1?#G6IY'N19C7TC!T62`L,7@N0=IB*?.,<YXQFOZ%?A;KFBV&D6
M'A>R\1Z5KFJ^&;&"SO$@O8Y;D&.-8R\B*Q9<D9.[UHHSG*_,K'F^(_".0Y/#
M"O(\7]8]I"\]4[;6=UM>[T>JL=F8A)@$9!X/%?`G_!#K_@JKXS_X*@2?&=_%
MWA[0/#X^&OB&#1K`:8TA-PC_`&G<\A<GYOW2]/4U]^QR;V'(X_,U^,?_``:'
M8'_#59Z9\<VQ_6^K>Y^6IW1^S80^6.,?I7Y]Z5_P5E\::A_P7-^(/[+S^&_#
MX\(>$O#*:Y;:H'D%]+(=+M[S:PSMV^9*5]<**_0@9*]N:_$_PU_RM_?&T>GP
M^B_]1ZRHN-;%7]G;_@O+^VY^V#I_B34/A-^S9X4\<Z3X9U>31[ZYM+XQ"WG4
M;U0B21228RC9&1R!UKK_`!E_P6^_;4_91T5_%?QK_8XO;#P+:$-J&I:1<M,U
ME'SEI#&S[``"=S`*,C)%6O\`@T%(3]G[]H/LH^)!_P#2&"OUTU.U@U2T>VN(
MHKBVN08989%#I*C##*P/!!!P01S2![GC'[`_[?/P[_X*/_L^:=\1/ASJ1N]-
ME<VU_93E5O-%NU`+VTZ`_*X!#`]&5E8'!KY\_P""J/\`P7J^&?\`P3:\26O@
MFVL;WXC?%G4=BP^&-'?>]F9<>4+EE!*O)P4B4&1@<X`()_-']@K]K.U_X)=?
M%K_@I/K?@C[))X0\"E'\-6).ZR759+^>ULD'8JKO@J.J0^U?7_\`P;:_\$S+
M?1/A)#^U1\5%E\7?&KXPO-KEIJFK*);C2[2=V/GIN'RSW/,C..1&R(I"@@@6
M.6T+]NS_`(*G?&VQC\0>%_V;O!_A31+S$EM9:VR6]XT;`,I9)90Z_*<?,`<Y
MR!5GX:?\')7Q#_9<^*FF^"?VR?@1KWPHGU*3RH]?L;:1K)AD9D`.5E10<MY3
MLR@YVU^P*PL,$[22.3ZFO-/VN?V1O`?[;OP.UKX=?$C0K37?#FMPE&#C$]C+
M_P`L[FWD^]%-&V&5UYSUR"00+G9_#_X@:+\3_!VG>(_#NIZ?K6@ZY;)>:?J%
ME*LUO>PN`5D1UX((-?,W_!4;_@KY\+?^"5GPYM-2\:W,NK>+-;C9]%\,V#J;
MV^13AIWSQ!;JQ`,KX!;Y5#'BO@#_`((F?M$^(?\`@E;^U;\?/V.?BEJ\NK>&
M_AWIM_XW\'7TXV$VUO&)[F-,]$FMW2=5`"H\=QC[U87_``0R_9(F_P""N/[5
M_C[]MCXZVS>);6#Q`;3P/H]ZOF622P<I,8VX,5JC(D*'*^89)""RJ0#2.V\)
M?\%3/^"CG[9-A_PDWP@_9GT/PUX+G`DL)_$:?9Y+V,Y`9//=&93P=P0`C!!(
MI[_\%_OVE_V$/%UA9_M=_LV:CH?AB[N$MV\3^'HRUJ&)X*R`M"S'DB,NC-M.
MT&OV2CMG`.6+9Z`\`>E87Q.^&7A_XQ>!]6\+>+-'TSQ#X;UZU>SU'2[^!9[6
M\A<89'1N"#Z]1CCF@1\T_M:_\%,M#\(_\$J?&O[2OP?O]"\<Z=HNC)J6E-([
M?9YI#/%$\4RC#QNF\AD;#*PP<5\<?M9?\'!?Q-^`7_!-_P#9I^,NE>"O!][X
M@^-:7IU.QG:;[-9-#O""':=QSM&0<DUA_MG?\$>=*_X)5_\`!)W]L)O`_P`2
MO%6L_#OQKHB75KX/U2WC>#0YQ?P%)([C.]R(OW1+`%P%+%F`-?)W[6=U)8_\
M$G/^"8D\+;)8?%2,C8!((OUP>F/TH!'[2_\`!(G_`(*6:'_P5!_9&TKQY8PV
MFE^)["=M+\5:+%+O.DWZ#)VYY,,J;9(V(Y5L9)4X^II\31E58Y/IWYK\,OVH
M]#U/_@W3_P""P=A\9/#=K-'^S1^T1>&U\5:?`A-KH=V[F68!1PGER.]S#@#$
M<EQ$.`!7[?>%?$=AXIT"QU33+NWO],U.!+JTNH'#Q7,+J'21&'!5E((QV-`-
M'PE\'O\`@J5X^^*7_!6_X_\`[.EOX4T";2OA7X1DUS1+F)W%[J5T%M?+BDR=
MNUFN".,=!S7@MI_P4F_X*:-:1%_V,]'5RHW#^THUY[\>=Q4'[`V%_P"#KW]J
M\C!(\$1?^AZ77Z_*4..`10!^1O\`P\G_`."F7'_&&FD9'_43C_\`CU>]_`S]
MKW]L'Q;X&^'-[XW^`EMX:US7O%MQIWB*QA83KINEJ(!'<%Q(0F0TS;N<F,#%
M?>K,"2,`9IRX?C&!^AH%<A_T7UC_`#HJQY:_W5_*B@#^?/\`X+Z6_B<_\%%/
M$#>+TN3X>>PM/^$8^U`FS^R^4/,\O/RAO-W;QUZ5;\/S:5XA_8(^"'@[XH#]
MH#QUKOB76=7@^'WPI\$>('TJ7Q=I.Y"MQ?,2'CLH760)(6&%;@%>1]F_\%4_
M^"QOAS]GSXX?\*SL/A=X9^)6K>&Q#<:I/X@53:6+R*'$,(*,3)LVDMP!D<&O
ME[XF:G;_`+1,VF?$CX>>)-8@^*'[:/BR/X20:GK,2+)\'-#@AWW^F6`BPKET
M#;)4"EE=<X8N:YX1C[66MWV/WGC+-\VJ\#9?A<3ERI44X\M6Z?-9.UEO'F6K
M;W.U_82_X(S:'^V)I3>-O$'PN^%GP`\&I8&W\(7OPA\>7=_XMMKZ.9DDDO=2
MAD>TN"A5D9<,PD0@X((KO?\`@HY_P2D/[.?P,^,?Q,\.>-+K5_#>L_!O4]'^
M*.F>(H?MEUXYO[*S+:;K;.NU%U".5=SS$`G&0,LQ/U#_`,$0?B?X0^(/_!.K
MPA;>!O`P^'WASPK?:IX9L]%:\6[DQ87TMNUR\H5=\LS#S)&P?WDC<G@GV?\`
M;+^,VA_`O]G/QAK.MZMX`TIO['NH[%?&>J0Z=HU[<^2WEP3R2\&-FP&`#$@]
M#70?@Y^1GPN\:_$*\^)'Q,;X?ZEK6H>,-%_9`\)I9007DDLEG+*\37+(@)"W
M/V<%TXWYVXZU\H?\$^-8\3:;^W#\++CX<S7K>*KKQ)9H3:N[2W5JTJBZ%SSE
MHO),ADW\#&>M>P?LV^)X/B?X!U>Q\.>.M;'A33]0'Q+_`&E?C1X:AN+./6;J
MVE4V'A?0IF1"T2R*D:>6%3`W#Y?E;Z\_8Q_X+>?#+QM^UM8Z9>?`_1OANWCN
M_72[7Q'9-;S7JW$SXB6[V1J0)&*JS*Q`9AG(YKFK13G%N5C]V\+<VS+"9#F=
M/!Y;]9@X^]/3W?=:LT]967O66OWGZKVX47)```#';[5^-/\`P:'C`_:K&<_\
M5S:_SO:_92S.+@+C!!.1UQUK\:_^#0P,R?M6$*3CQS;=/K>UU,_"%LS]H$^X
M/I7XH>&_^5O_`.-W_9/HO_4>LJ_:T%\8QC%?BCX:)'_!W]\;,@_-\/HO_4>L
MJ0T=7_P:'D#]GK]H$D$C_A91R!U/^@P5VO[?OQ%_X*7^.OC!KWPH^$GP_P#A
MQI'A'4LBS^).G7OV<K9R`X#FYE9H+A%!5_+A<AN4/*FN-_X-!0'_`&?_`-H(
M'D?\+);_`-(8:_7];=#GY1GI0#W/Y_O^"F__``2,_P"'7W_!OOXOTK^V#XO\
M?^+O&NDZSXVURW1E@F(,J1PQ[OG:"-Y!AG^9W=G(!.!^T'[`6OZ+XI_8D^#F
MH>'#&VA77@G2'L=A!"Q?9(@!D=Q@@^X[5;_;?_99T/\`;5_92\=_"GQ`?)TW
MQKI4NGBY"[GL9R-T%RH[M%*J.!WVXK\F/^"-7_!4&^_X)3>.[_\`8T_:RE3P
M+<^#[IT\(^)KXE=*:VE<NL3SD;5M9&8O#.?D7>8W*E0*`N?N`)%;H<U',PQC
M)).1]*HZ#J]KKVEV^H:;<6U]8WL8FM[FVE6:&9&&0RLI(92.01P:^5_^"GW_
M``6%^$?_``3'^&=[?>*M>TS5?'+PN=&\(65TDNI7\VWY&E13F"W#8+2R;5`R
M!N;`()'Y8_\`!7B"7XC?\'`OCFR\(.5U71O@9KL>KR0IO^9=`OV9#CG)CEA3
MGNRU]Z?\&M7B;1_$'_!&CX<Q:6\!DTN\O[2_5"-T=R+AF;=CH2K*WK@BO)_^
M#?/]@;QMX_U#XJ?M5?M!:7)'X^_:!AFL]-TZZC:.6ST2=@TTC1L,Q_:"(E12
M`RPVZ'^,BOF_]DSX^ZQ_P;,_\%$O&7P;^+-KJ;?LY_%2^?6O#FO00//'IO.U
M+R,*"9`J%8KJ%<R)LCE`9<A@IL_?T=!CI36V!LG`(%<O\*_C#X:^.7@:Q\2^
M#/$.B>*O#VHQK):ZCI-['=VTRD9&'0D9Z<=1W%>7?MT_\%%OA/\`\$\/A3>^
M*_BCXIL-*5(B;/1X)%FUC69.BQ6ML#OD8GJV`B#+.RJ"0"/*/^#A1@W_``1C
M_:#P`!_PCL?_`*5P5^/W[7W/_!)/_@F0?^IG7_TO6OH7XN_MS_M"_P#!1S_@
MBQ^UG\5/B'X5\/>!_@YJ.AK;>!=.AM7&I7P&H0;KAYF.)(D0!-ZJ%=RQ7(6O
MGG]KP@_\$D?^"9!SD'Q.N/?_`$]:`U/WL_;M_8O\*?M^?LK^*_A?XQ@1],\1
M6N+:YV[I=+O$&8+J//1XY,'C&1D=":_.;_@W>_;1\6?`'XG>+_V&?CE/]D^(
M'PHN)4\'3W!(_M33E^9K5&/WE1&6>`\[H)=O_++%?KT!F%03U`SCKTK\L_\`
M@X\_X)[>)?&/AGPW^U1\%XYM.^-7P)9-1GEL%Q<ZMI4+&4Y`YD>W)=@O5HY)
MDYRHH%'S//OV.].U#5_^#HC]L>TTB\73]6NOAVT5E=,"1:SM_9HCD.,Y"L0?
MPK3M?^"6'_!39;9`?VW?#9(7!)M9V)_'[-S]:\B_X(%?M56G[;__``7M^,WQ
M8M-/ETL>-_AA!=W%JY#+#<)+IL4X0CK&9$8J>NTC/(-?NRB,%```%!3W/RS^
M`/\`P3<_X*&^!?CSX)UOQO\`M@^'_$W@W2-;M+S7=(CMYT?4[))`TUN,P`9=
M`R\D#G.>*_4RWPPW*3M;)&:4Q$G)4'\:2/(<`X!]*!7):***!'Y=?\%/_P#@
MAMXI_:J_:,O?B5\-_$?A^SO?$Z01ZUIFL^9'&LL:!!/$Z`Y!0#*$=1P:\E\6
M>"_@%^P?\3_V;_`/B'XTP-XC^`GC*[\9^,#!H5Q=PWU_>6QC\LO$2MN(@5P&
MW$(N6P217[,8"L,@9)&:_GH_;@_X)E_&_P`$_MB^.K:Q\#>)?&5GXM\1WNL:
M/JNGPF>+4HKNX:91(_\`RSD7?L</C&W(RN"<*L7#WH*[9^[\!YC'BRBN'>)L
MP]EA</#F@O=BVUHKR:U44VTGK;T-GX5>`/'_`.SG\0KKPY\/+B.;]H/]G.[U
M7Q=X6M=/O2;'XU?#S7KM[V<6@Y4W,3R.R[0=KJ`=Q3Y8?#?C37/VV?%OAWPK
MX>^-WPL^.7B+1-2DN]&^&?[37A*73/$WAV[ECPZQRIM6\V`#Y#N#;`=HXQ[5
M_P`%`9/$O_!,O]DS]F#P[8:;HEM\9])T"^T8^.H[5+J^\/6Q`>XL;*60$*6,
M@CW[3M2-MN-Q-1_\$F?C9XE_X*!^/?&?@+XG0Z-XW\7:#X7N=5\%^.=5TFWD
MUSPM<NKVK#[6L8<JPFRK?>&UADC&*=:/-R=3Y:7AACI9-5XBH5(RPL)N-[^\
MXJ7+SV[=;7N)\(?%?A_XX^+/%7PA^-?[7VB:V/%FB7'@VP\'>#_""Z+X&T2^
M:6-X'@FV@2S0SQ)L8D!N5W$,16Q^R'_P;T?$?P%^U-X:U_XA^*/"?_")^#M6
MAU9?[(DEEN]8DMY`\4>QU`A1G56;)8XR!US7Q7X<_P""7WQWU;XP6OPT_P"%
M>>(K/74NTLI+UX"NG6ZK(,W?V@_+Y0`\P,#D\8&:_I&\)Z3+H>@:;8373WD]
MA:Q6TEPX^:X9$52Y]V(S^-9TU[1\TX['V/%F-CP3A(9?PMF/M:>+A>HO=DT[
M6YDTO=YD[=]"W/?+80S74I.R!6DD(7L`2<?A7\QB>&/^">^GZUK-SIW[27[4
MFB_VQ?S7ES#IVD/:QM*TCD[A&@#%2S`$Y(!-?TX>*,)X6U(8`)M)?_0#7\/W
MB*1CX?U?R6)F,ESLVMAL^:^,5U,_`HJY^BL=G^P+,JNG[57[7$J$@C_1+AE;
M#?[O/3%?3GA+_@I+^P5X*_X*/Z_^TFGQ2^+\WBS7O#D/AVXTR;PR_P!B2%-.
M@L%E'R;]Q2`-DG&]F[<5^:/_``4GU#P=??MS?$&7P$WA_P#X1-GTS[!_8H1+
M#(T;3Q+Y83C/G"7=C^/?WS7N7_!.;5/@-?\`[*.A:'\2CX5T_P`<O\2/%>M:
M1K.H""1H8+;0=,$&G7:M\QM+MI;KRF;Y5N+?Y02S&D-Q/MW_`()>_P#!5[]A
M?_@EIX+\;Z'X4^(WQ:\26_CC7CKUR^K^%9-]O+Y*Q%$\M5^7"@\\\U]/1?\`
M!UQ^QV]P\2>)_&;S*,M&/#-P7'U'6OYDMTKZ$-CE9RIQ\_S'KT]_3KS7W)^V
MYX@T6[_95QX$N/V9S\$+C3='A\'6%O:0)\0;#4T$9OI#)&!>?:VD\[[2;IFM
MFB*[`#MH#E1^QC?\'5?[(!))\0^...?^16N<#]*\!_;D_P""P?\`P39_X*5_
M#Z+0_B@GBW7_`.SBPT_5;3PW<P:GI);[PAN$&Y0>Z-E#W4U^*O[+%WX"M?VG
MOAK+\4A'+\-4\269\3JX=HC8^9\XE6/YS"&V&0)\QC#XKZ`_X*1ZI9S_``K\
M%6_C'4/@5JWQJ3Q#J$OVSX56]G;Z6GA5HE^R17/V-4A+";)@#+YZQ9$AS0#C
MJ;-WX6_9"^'TLMO\/?VU_P!H[P'X4N)&5]+?PM>;8XR<[%:&6)"?<H*]R_8=
M\9_\$N_V3/'EMXU\1^)OBK\9O&]M,+J/4O%GAN>>T28$,LPM5&UW!Z-*TF.,
M8(S7RE_P2<\3^`/"?[6FHZA\2=>\-^&?#</@[4Q%J^LZ-:ZU!IEXQA$,R6=R
MK13R+E\*ZD8+'M7E7[7]SH4_[7OQ7?PYHNE>&/#C^+-0;2])TR]BO+*PMC*?
M+6"6/]V\;#YUV?(`^T<**!N)_0W#_P`'5_['1N&A'B?QDTRC)C_X1BYWKT[=
M0.E><?M6?\%ZO^"?7[;/PEO?`_Q0M_$WBKPY=GS1#=>%+I9;*4`@3P2KAX95
MR<.A!Y(Z$@_D[\7?CM\*M$_X),?#+X=6GAO2-8^*'B72DU&?5[;3]/1O"US;
MZW=-)<37:C[=)=S6@B@%NQ\CRF5^6SCP[]CV_P#A_9?M;?#:?XIK:S?#B/7[
M=_$$=P"]K]GP^W[0%^8VPF\GS@O)B#XSTH$HZ'TUK?@_]AWPMXCOM2^"/[6G
M[1/PNM+J3=]DB\.75U&O!W9D@>)G."0"X)YY-=Q^S7;?\$R_A#\0[;QE\6_B
ME\:/CIKMM(KC_A)M`N8=.F<<@2Q9+S*",A))"IQRI'%>,_\`!2S4-,G^'_PZ
M3Q3J7P:U;XYKJ&J/KEU\,(+.#1?^$?98_P"S(K@6:)`;@2>;LPOF"`@2$M6?
M_P`$D?%WPZ\&?M&>/-2^)GB#P_X7T&'X<7Z6&LZMH%KX@CTK4)-2TV.*XBLK
MH-%/,D;RG:1D1^:W0&@''0_63]L/_@O#^P_^V-^R#XL^#5_XM^('AWPUXLTV
M/2S+I'A&6-[&%)(Y%6%2NP*/+``QC;7S-\3?VL/^"?GQ/_9M_9^^%]U\6_C1
M;:;^SS?_`-I:/<Q^%B;G4V\\2XG!3&T'CY0./>OS._:KFTC_`(:G^*(T'0=(
M\)Z#_P`)5J(TW1=,U&/4+#3;?[0P2.">/Y)8L?,&3Y<-A>,5]+>!/AG\!+C_
M`()4:EX7U#QAX;3]HSQ/;R_$S33)!DV5O:2&&'1FO?N1336T<\K6Q!+/)'R"
M!D!1/V/;_@ZK_8]LXV9_$GC947DEO"]R`/TJ-_\`@ZH_8YU:S=1XA\97%O."
MK_\`%+7$B2+T*GC!!&017\XWP4\9#PC\9/!6M`:9Y=AK]A+,-0MHKJT\@W$:
MRB:*4,CIY9;<&!'6O0_^"AWC+1O'7[>_QBU#PXWAE/"X\57=IH0\/V5O8Z9_
M9\+"*V\F.`*F/+5?G`!<\DDF@.1'Z)_LD?MC_P#!.C]B7]J#XF>/_`OQ&^+N
MG/\`$K0K_0?[`/AV3[+HL%Y,D[FUPHD78Z'8"2%!QV%>#IIG[`UG:J)/VJ_V
MN56)0&8VDZ@>_P!W`KSE-2\&R?\`!#JW@M9]#C\>Q^-;XZBL']AC4)+8WEK]
MG$YG3^U"@42&/[&P3!;S<KC'D'[`]WX7M/V]?@E)XS;13X.3QMIYUL:L$;3_
M`+('._[0'^3RNFX-\N.O%`^4^IX+3]@2ZC#Q?M6?M<R(W1EMKAA^BU^RW_!O
MYJWPCN/V,M5L?@SX[^(/Q"\,6/BF[-QJ?C&%X]12Y>&`M$-PR8U4*0?5C7\^
MG_!2/4O#%WXW\")!<?#&[^)D&D7,?C^[^'D,$'AZYN?M;_82%@"VYNUML"9H
M%"'Y.K9-?LO_`,&A#?\`&OSQSD@G_A.[@9SG_ERM*"6M#]8****"2%ER`23D
MXIC)^[<@D;<\=J**;8UL>1_M:?L5_#[]N?X>0^%/B#I4U]96L@O+*ZM9VM[S
M3YL8\R&5>5)'!!R#W!K"_8M_X)T?##_@G]IVJ6/@#3M0-[X@\M]2U75+LWFH
M7@0G8C2$`*BY)"JJC))HHJ5%<]['U5+,L6L@GA55DJ?.O=YGR[)_#>V^NVY[
MJKDN(S]TBIT4`]!E:**I;'RKZD6JP)/931R*'CD0HRGH01@C\J^.3_P;R?L;
M%V8_`SPPS,2Q)FN3DDDD_P"L]2:**E,&)'_P;R?L:H"J_`OPNH7@8FN1_P"U
M*&_X-X?V-'8[O@5X6;(P<RW'/.?^>E%%,+B_\0\O[&W_`$0SPQC_`*[7/_QR
MA?\`@WC_`&-5D+CX%^%@QZD2W`)_\B444!=@/^#>7]C<=/@;X8_[_7/_`,<I
M%_X-XOV-(CA/@5X64-U`FN1_[4HHH$VQ7_X-XOV-9!AO@7X689SS+<'G_OY0
MO_!O'^QJ@`7X%^%P!T'G7.!_Y$HHH&FP'_!O%^QJK%A\"O"P+=3YUSD_^1*4
M_P#!O+^QL1@_`SPN1_UVN>?_`")110"8U?\`@WA_8T087X%>%E!YXEN1_P"U
M*5_^#>3]C5@,_`OPN=O(S-<D=/\`KI110%V"_P#!O'^QJB[1\"O"P7T\VYQ_
MZ,II_P"#>#]C1P0?@5X6()R?WMQR?7_6=:**!-CS_P`&\O[&S*0?@7X7(;K^
M^N?_`(Y2+_P;R?L:J`!\"_"X`Z`37(`_\B444#NQJ_\`!O#^QH6W_P#"B?"H
M;U\VYS_Z,IS_`/!O)^QJZD'X%^%R#P?WUSS_`.1***!)L!_P;Q_L:J@4?`OP
MN%'837./_1E>]?LI_L:?#/\`8>\&7?A;X5^$[#P?H.HWS:C<6EJ\C))<,BH9
4,NS')5%'!QQ110)MGJ]%%%`S_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
